RUBY Stock Overview
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rubius Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.057 |
| 52 Week High | US$0.38 |
| 52 Week Low | US$0.0032 |
| Beta | 2.21 |
| 1 Month Change | 198.43% |
| 3 Month Change | 251.85% |
| 1 Year Change | -64.38% |
| 3 Year Change | -99.32% |
| 5 Year Change | -99.63% |
| Change since IPO | -99.76% |
Recent News & Updates
Recent updates
Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03
Aug 09Rubius: Poor Data, Punishing Environment, Beaten Stock
Jun 19Rubius Looks Attractive Before AACR Data Readout
Mar 21Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?
Oct 28
Our Read On Rubius Therapeutics
Jul 11Rubius Therapeutics EPS beats by $0.02
May 10Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?
Feb 25Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow
Jan 14Rubius Therapeutics EPS misses by $0.01
Nov 09Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers
Oct 28Shareholder Returns
| RUBY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.7% | -2.5% | -3.2% |
| 1Y | -64.4% | -3.7% | 19.3% |
Return vs Industry: RUBY underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: RUBY underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| RUBY volatility | |
|---|---|
| RUBY Average Weekly Movement | 54.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RUBY's share price has been volatile over the past 3 months.
Volatility Over Time: RUBY's weekly volatility has increased from 34% to 55% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 6 | Craig Jalbert | www.rubiustx.com |
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
Rubius Therapeutics, Inc. Fundamentals Summary
| RUBY fundamental statistics | |
|---|---|
| Market cap | US$5.16m |
| Earnings (TTM) | -US$179.67m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs RUBY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RUBY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$179.67m |
| Earnings | -US$179.67m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RUBY perform over the long term?
See historical performance and comparison